Literature DB >> 30424960

Childhood Moyamoya: Looking Back to the Future.

Nomazulu Dlamini1, Prakash Muthusami2, Catherine Amlie-Lefond3.   

Abstract

Moyamoya is a chronic, progressive steno-occlusive arteriopathy that typically affects the anterior circulation arteries of the circle of Willis. A network of deep thalamoperforating and lenticulostriate collaterals develop to by-pass the occlusion giving rise to the characteristic angiographic "puff of smoke" appearance. Moyamoya confers a lifelong risk of stroke and neurological demise, with peak age of presentation in childhood ranging between five and 10 years. Moyamoya disease refers to patients who do not have a comorbid condition, whereas moyamoya syndrome refers to patients in whom moyamoya occurs in association with an acquired or inherited disorder such as sickle cell disease, neurofibromatosis type-1 or trisomy 21. The incidence of moyamoya disease and moyamoya syndrome demonstrates geographic and ethnic variation, with a predominance of moyamoya disease in East-Asian populations. Antiplatelet therapy and surgical revascularization procedures are the mainstay of management, as there are no available treatments to slow the progression of the arteriopathy. Future research is required to address the major gaps that remain in our understanding of the pathologic basis, optimal timing for surgery, and determinants of outcome in this high-stroke risk condition of childhood.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Arteriopathy; Childhood; Moyamoya; Pediatric moyamoya; Stroke

Mesh:

Year:  2018        PMID: 30424960     DOI: 10.1016/j.pediatrneurol.2018.10.006

Source DB:  PubMed          Journal:  Pediatr Neurol        ISSN: 0887-8994            Impact factor:   3.372


  3 in total

1.  Remote ischemic conditioning for the treatment of ischemic moyamoya disease.

Authors:  Jia-Yue Ding; Shu-Ling Shang; Zhi-Shan Sun; Karam Asmaro; Wei-Li Li; Qi Yang; Yu-Chuan Ding; Xun-Ming Ji; Ran Meng
Journal:  CNS Neurosci Ther       Date:  2019-12-08       Impact factor: 5.243

2.  RNF213 variant in a patient with Legius syndrome associated with moyamoya syndrome.

Authors:  Giulia Romanisio; Cristina Chelleri; Marcello Scala; Gianluca Piccolo; Barbara Carlini; Laura Gatti; Valeria Capra; Federico Zara; Anna Bersano; Marco Pavanello; Patrizia De Marco; Maria Cristina Diana
Journal:  Mol Genet Genomic Med       Date:  2021-05-03       Impact factor: 2.183

3.  PHACTR1 is associated with disease progression in Chinese Moyamoya disease.

Authors:  Yongbo Yang; Jian Wang; Qun Liang; Yi Wang; Xinhua Chen; Qingrong Zhang; Shijie Na; Yi Liu; Ting Yan; Chunhua Hang; Yichao Zhu
Journal:  PeerJ       Date:  2020-05-05       Impact factor: 2.984

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.